Boehringer Ingelheim advances next generation triple-agonist peptide for obesity
Boehringer Ingelheim has announced the advancement of BI 3034701, its long-acting potential first-in-class triple-agonist peptide, in development for the treatment of obesity.
More than one billion people worldwide live with obesity, a complex, chronic disease associated with heightened risk of liver, cardiovascular, renal and metabolic complications.
Progression follows the completion of a randomized, placebo‑controlled Phase I study in healthy volunteers and people with overweight/obesity, where BI 3034701 demonstrated a favorable safety and tolerability profile and showed encouraging weight‑loss.
BI 3034701 was developed in cooperation with Gubra. Boehringer Ingelheim is solely responsible for further development and global commercialization of BI 3034701. The progression of this asset further expands Boehringer Ingelheim’s patient‑centric CRM pipeline portfolio.
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health.
